Sage Therapeutics (SAGE)
(Delayed Data from NSDQ)
$10.99 USD
+0.52 (4.97%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $10.97 -0.02 (-0.18%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum D VGM
Price, Consensus and EPS Surprise
SAGE 10.99 +0.52(4.97%)
Will SAGE be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SAGE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SAGE
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical
Ardelyx (ARDX) Expected to Beat Earnings Estimates: Should You Buy?
SAGE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: SAGE Plunges on Study Failure, AGEN Down on Regulatory Update & More
Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
SAGE Rides on Zurzuvae Sales, Pipeline Setbacks a Concern
Other News for SAGE
SAGE Therapeutics’ Neutral Rating and Price Target Adjustment Following KINETIC-2 Trial Setbacks
Sage Therapeutics cut to Neutral at J.P. Morgan on pipeline concerns
Sage Therapeutics price target lowered by $2 at Scotiabank, here's why
Sage Therapeutics price target lowered by $2 at Baird, here's why
Sage Therapeutics just downgraded at JPMorgan, here's why